Erratum: Studies on the effect of the size of polycaprolactone microspheres for the dispersion of salbutamol sulfate from dry powder inhaler formulations (Pharmaceutical Research DOI:10.1007/s11095-012-0772-y);Studies on the effect of the size of polycaprolactone microspheres for the dispersion of salbutamol sulfate from dry powder inhaler formulations

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2445-2455

  Tuli, Rinku A ^a   George, Graeme A ^a   Dargaville, Tim R ^a   Islam, Nazrul ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Biodegradable polymers; Carrier size; Dry powder inhaler; Microspheres; Polycaprolactone

Indexed keywords

LEUCINE; MAGNESIUM STEARATE; MICROSPHERE; POLYCAPROLACTONE; SALBUTAMOL SULFATE;

AEROSOL; ARTICLE; BIOMECHANICS; COATED PARTICLE; CONTROLLED STUDY; DISPERSION; DRUG FORMULATION; DRUG MIXTURE; EMULSION; LASER DIFFRACTION; PARTICLE SIZE; POWDER; POWDER INHALER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STRUCTURE ANALYSIS;

EID: 84866732102     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0866-6     Document Type: Erratum

References (44)

1. Hickey AJ, Concessio NM. Descriptors of irregular particle morphology and powder properties. Adv Drug Delivery Rev. 1997;26 (1):29-40.
2. Young PM, Cocconi D, Colombo P, Bettini R, Price R, Steele DF, et al. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing". J Pharm Pharmacol. 2002;54:1339-44.
3. Islam N, Stewart P, Larson I, Hartley P. Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy. J Pharm Sci. 2005;94 (7):1500-11.
4. Begat P, Price R, Harris H, Morton D, Staniforth J. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. KONA. 2005; 23:109-21.
5. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci. 1996;27(5):769-83.
6. Steckel H, Muller BW. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm. 1997;154(1):31-7.
7. Zeng XM, Martin GP, Marriott C, Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm. 2000;200(1):93-106.
8. Karhu M, Kuikka J, Kauppinen T, Bergström K, Vidgren M. Pulmonary deposition of lactose carriers used in inhalation powders. Int J Pharm. 2000;196(1):95-103.
9. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm. 1998;172 (1-2):179-88.
10. Ganderton D. The generation of respirable clouds from coarse powder aggregates. J Biopharm Sci. 1992;3:101-5.
11. Lucas P, Anderson K, Potter UJ, Staniforth JN. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm Res. 1999;16(10):1643-7.
12. Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers: Fine particle multiplets as performance modifiers. Pharm Res. 1998;15(4):562-9.
13. Staniforth JN. Performance-modifying influences in dry powder inhalation systems. Aerosol Sci Technol. 1995;22(4):346-53.
14. Tee SK, Marriott C, Zeng XM, Martin GP. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int J Pharm. 2000;208(1-2):111-23.
15. Byron P, Jashnani R, Germain S. Efficiency of aerosolization from dry powder blends of terbutaline sulfate and lactose NF with different particle size distribution. Pharm Res. 1990;7: S81.
16. Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, et al. Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules. Powder Technol. 2010;201(3):289-95.
17. Hassan MS, Lau R. Inhalation performance of pollen-shape carrier in dry powder formulation: Effect of size and surface morphology. Int J Pharm. 2011;413(1-2):93-102.
18. Islam N, Stewart P, Larson I, Hartley P. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures. J Pharm Sci. 2004;93(4):1030-8.
19. IslamN, Stewart P, Larson I,Hartley P. Lactose surfacemodification by decantation: Are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate fromlactose-interactive mixtures? Pharm Res. 2004;21(3):492-9.
20. Louey MD, Razia S, Stewart PJ. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures. Int J Pharm. 2003;252(1-2):87-98.
21. Ooi J, Traini D, Hoe S, Wong W, Young PM. Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. Int J Pharm. 2011;413(1-2):1-9.
22. Podczeck F. The relationship between physical properties of lactose monohydrate and the aerodynamic behaviour of adhered drug particles. Int J Pharm. 1998;160(1):119-30.
23. Srichana T, Martin GP, Marriott C. On the relationship between drug and carrier deposition from dry powder inhalers in vitro. Int J Pharm. 1998;167(1-2):13-23.
24. Bell JH, Hartley PS, Cox JSG. Dry powder aerosols I: A new powder inhalation device. J Pharm Sci. 1971;60(10):1559-64.
25. Gilani K, Darbi M, Barghi M, Rafiee-Tehrani M. Influence of formulation variables and inhalation device on the deposition profiles of cromolyn sodium dry powder aerosols. Daru. 2004;12 (3):123-30.
26. Kassem NM, Ho KKL, Ganderton D. The effect of air flow and carrier size on the characteristics of an inspirable cloud. J Pharm Pharmacol. 1989;41:14P.
27. Cline D, Dalby R. Predicting the quality of powders for inhalation from surface energy and area. Pharm Res. 2002;19(9):1274-7.
28. de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Kussendrager KD, Frijlink HW. Air classifier technology (ACT) in dry powder inhalation Part 2. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation. Int J Pharm. 2003;260(2):201-16.
29. Donovan MJ, Smyth HDC. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations. Int J Pharm. 2010;402(1-2):1-9.
30. Byron P, Jashnani R, Germain S. Efficiency of aerosolization from dry powder blends of terbutaline sulfate and lactose NF with different particle size distribution. Pharm Res. 1980;7:S81.
31. Tuli RA, Dargaville TR, George GA, Islam N. Polycaprolactone microspheres as carriers for dry powder inhalers: Effect of surface coating on aerosolization of salbutamol sulfate. J Pharm Sci. 2012;101(2):733-45.
32. Wang S, Guo S. Disodium norcantharidate-loaded poly(e-caprolactone) microspheres: II. Modification of morphology and release behavior. Int J Pharm. 2008;353(1-2):15-20.
33. Alway B, Sangchantra R, Stewart PJ. Modelling the dissolution of diazepam in lactose interactive mixtures. Int J Pharm. 1996;130 (2):213-24.
34. de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW. Air classifier technology (ACT) in dry powder inhalation: Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int J Pharm. 2003;260(2):187-200.
35. Voss A, FinlayWH.Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm. 2002;248(1-2):39-50.
36. Coates M, Chan H-K, Fletcher D, Chiou H. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res. 2007;24(8):1450-6.
37. Coates MS, Fletcher DF, Chan H-K, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. J Pharm Sci. 2004;93(11):2863-76.
38. Chew NYK, Chan H-K, Bagster DF, Mukhraiya J. Characterization of pharmaceutical powder inhalers: Estimation of energy input for powder dispersion and effect of capsule device configuration. J Aerosol Sci. 2002;33(7):999-1008.
39. Concessio NM, VanOort MM, Knowles MR, Hickey AJ. Pharmaceutical dry powder aerosols: Correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Pharm Res. 1999;16(6):828-34.
40. Shur J, Harris H, JonesM,Kaerger J, PriceR. The role of fines in the modification of the fluidization and dispersionmechanism within dry powder inhaler formulations. Pharm Res. 2008;25(7):1631-40.
41. Traini D, Young PM, Thielmann F, Acharya M. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. Drug Dev Ind Pharm. 2008;34 (9):992-1001.
42. Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HDC, Mulder T, et al. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J Pharm Sci. 2007;96(5):1302-19.
43. Ibrahim TH, Burk TR, Etzler FM, Neuman RD. Direct adhesion measurements of pharmaceutical particles to gelatin capsule surfaces. J Adhes Sci Technol. 2000;14(10):1225-42.
44. Linsenbühler M, Wirth K-E. An innovative dry powder coating process in non-polar liquids producing tailor-made microparticles. Powder Technol. 2005;158(1-3):3-20.